DNAJC9-AS1: A Potential Drug Target and Biomarker (G414245)

Target Name: DNAJC9-AS1

NCBI ID: G414245

DNAJC9-AS1

Other Name(s): DNAJC9-AS1 variant 1 | DNAJC9 and MRPS16 antisense RNA 1, transcript variant 1 | DNAJC9 and MRPS16 antisense RNA 1 | C10orf103 | bA537A6.3

DNAJC9-AS1: A Potential Drug Target and Biomarker

DNAJC9-AS1, a variant of the DNAJC9 gene, has been identified as a potential drug target and biomarker for various diseases. DNAJC9 is a non-coding RNA molecule that plays a crucial role in the regulation of mitochondrial dynamics, which is essential for energy metabolism and cellular processes. The DNAJC9 gene has four splice variants, including the DNAJC9-AS1 variant, which has been shown to have unique functional characteristics compared to the other splice variants.

The search for potential drug targets and biomarkers has become an important area of research in the pharmaceutical industry. Drug targets are molecules that are associated with the development or progression of a particular disease and can be targeted with drugs to prevent or treat the disease. Biomarkers are molecules that are associated with the disease and can be used to monitor the progression of the disease and the effectiveness of treatments.

DNAJC9-AS1: A Potential Drug Target

The DNAJC9 gene is known to play a role in the regulation of mitochondrial dynamics and is involved in various cellular processes, including the transport of oxygen and electrons across the mitochondrial membrane and the import of nutrients into the mitochondria. The DNAJC9-AS1 variant has been shown to have unique functional characteristics compared to the other splice variants.

One of the key features of DNAJC9-AS1 is its ability to form a stable complex with the protein p120catenin, which is a component of the mitochondrial outer membrane. This complex plays a crucial role in regulating the transport of oxygen and electrons across the membrane and has been implicated in the development of various diseases, including cancer.

In addition to its role in regulating mitochondrial dynamics, DNAJC9-AS1 has also been shown to be involved in the regulation of cellular processes that are essential for the survival of cells, including cell growth, apoptosis (programmed cell death), and inflammation.

DNAJC9-AS1 has also been shown to be involved in the regulation of various cellular processes that are essential for the survival of cells, including cell growth, apoptosis (programmed cell death), and inflammation.

Potential Therapeutic Strategies

The unique role of DNAJC9-AS1 in the regulation of mitochondrial dynamics and the import of nutrients into the mitochondria makes it an attractive potential drug target. Various therapeutic strategies have been proposed to target this protein, including:

1. inhibition of DNAJC9-AS1 function:

Inhibition of DNAJC9-AS1 function would target the protein and prevent it from regulating the mitochondrial dynamics and the import of nutrients into the mitochondria. This could be achieved through various methods, including the use of small molecules, antibodies, or genetic modifiers.

1. modulation of DNAJC9-AS1 expression:

Modulation of DNAJC9-AS1 expression levels could be an attractive therapeutic strategy by targeting the gene and regulating its expression levels. This could be achieved through various methods, including the use of drugs or genetic modifiers that modify DNAJC9-AS1 stability or activity.

1. modulation of DNAJC9-AS1-p120catenin interactions:

Modulation of DNAJC9-AS1-p120catenin interactions could also be an attractive therapeutic strategy by targeting the interaction between the protein and its protein partner. This could be achieved through various methods, including the use of drugs or genetic modifiers that modify the stability or activity of the interaction.

Conclusion

DNAJC9-AS1 is a non-coding RNA molecule that plays a crucial role in the regulation of mitochondrial dynamics and is involved in various cellular processes. The unique function of DNAJC9-AS1 compared to the other splice variants makes it an attractive potential drug target and biomarker for various diseases. The inhibition of DNAJC9-AS1 function, modulation of DNAJC9-AS1 expression, and modulation of DNAJC9-AS1-p120catenin interactions are potential therapeutic strategies that could be explored for the treatment of various diseases. Further research is needed to

Protein Name: DNAJC9 And MRPS16 Antisense RNA 1

The "DNAJC9-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAJC9-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets